Molecular changes in CML CP progenitors treated with IM and SB216763. (A) CML CP (n = 5) CD34⁺ cells were exposed to IM (1μM), dasatinib (0.15μM), or SB216763 (5μM) alone or in combination with IM or dasatinib for 24 hours in SFM containing high 5GF concentrations. Representative immunoblots for active β-catenin, total cyclinD1, C/EBPα, p27, ATF5, and phospho-mTOR (pSer^2481/2448) in a representative CML CP patient sample are reported. Total β-actin levels are reported as a loading control. (B) CML CD34⁺ cells were treated with the indicated drug(s) and then analyzed for the presence of MDC-positive autophagosomes, distinct dot-like structures trapped in acidic, membrane-rich organelles distributed in the cytoplasm or localizing in the perinuclear regions of CML cells (magnification, 60×). The numbers indicate the percentage of autophagy induction for each drug treatment condition.